Brief: Candel Therapeutics Announces Release Of Initial Data On Can-2409
27/05/2022 24:39
May 26 (Reuters) - Candel Therapeutics Inc CADL.O :
* CANDEL THERAPEUTICS ANNOUNCES RELEASE OF INITIAL DATA ON
CAN-2409 IN A PHASE 2 CLINICAL TRIAL SHOWING CYTOTOXIC T CELL
RESPONSE AND DISEASE CONTROL IN PATIENTS WITH NON-SMALL CELL
LUNG CANCER
* CANDEL THERAPEUTICS INC - EVIDENCE OF TUMOR REGRESSION IN
BOTH
INJECTED AND UNINJECTED LESIONS WITH CAN-2409
* CANDEL THERAPEUTICS INC - INDUCTION OF LOCAL AND SYSTEMIC
CYTOTOXIC T CELL RESPONSE AFTER EXPERIMENTAL TREATMENT WITH
CAN-2409
Source text for Eikon: ID:nGNXbgfV9r
Further company coverage: CADL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Candel Therapeutics
See all newsBrief: Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints In Patients From Phase 3 Trial Of Aglatimagene Besadenovec (Can-2409)
Candel Therapeutics reports Q1 loss
Brief: Candel Therapeutics Q1 Net Income USD -8.861 Million
Brief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Candel Therapeutics Inc Extended Survival Tail Observed In Trial Of Aglatimagene Besadenovec